Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

Partner | Cancer Centers | <b>UT Soutwestern</b>

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in Hodgkin lymphoma.

ABVD has been a standard of care for patients with Hodgkin lymphoma for many years, explains Rizvi.

However, around 30% of patients do not respond to ABVD and require an alternative treatment strategy, says Rizvi.

Early identification of patients who are unlikely to respond to ABVD will help optimize patients’ treatment, says Rizvi.

Moreover, developing refined therapies that elicit extended progression-free survival and overall survival should remain an area of ongoing research in Hodgkin lymphoma, concludes Rizvi.